Global Funding For TB R&D Declined Last Year, Report Says

“Funding for research and development [R&D] of new drugs, vaccines and rapid diagnostic methods for [tuberculosis (TB)] declined 4.6 percent in 2012 to $627.4 million after rising annually every year from 2005 to 2011, said [a report from] the Treatment Action Group, a New York-based AIDS research and policy think tank that also focuses on TB issues,” the Wall Street Journal reports. “Most of last year’s cuts came from private-sector donors, the group said, warning that reductions are likely this year as well, because major public-sector donors such as the U.S. government have been hit with budget cuts and across-the-board spending reductions called sequestration,” the newspaper writes, outlining some of the specific cuts and TB research efforts. “While the drop in funding wasn’t huge, it comes at a time of a worsening epidemic of drug-resistant TB, which public health authorities say can’t be confronted effectively without new tools,” the Wall Street Journal notes, adding, “The decline in investment for R&D is part of an uncertain picture overall for funding against TB, which killed an estimated 1.3 million people in 2012, but draws far less overall investment than HIV/AIDS, which was linked to the deaths of 1.6 million people that year” (McKay/Shah, 10/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.